This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

This study has been completed.
Information provided by (Responsible Party):
Jay Hoofnagle, M.D., National Institutes of Health Clinical Center (CC) Identifier:
First received: May 17, 2007
Last updated: May 31, 2013
Last verified: May 2013
Results First Received: May 1, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin
Drug: S-adenosyl methionine for Chronic Liver Disease

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Hepatitis C Treated With Peginterferon and Ribavirin Patients infected with hepatitis C virus (HCV) treated with peginterferon alpha-2a and ribavirin

Baseline Measures
   Hepatitis C Treated With Peginterferon and Ribavirin 
Overall Participants Analyzed 
[Units: Participants]
[Units: Year]
Median (Full Range)
 (41 to 65) 
[Units: Participants]
Female   8 
Male   16 
Race/Ethnicity, Customized [1] 
[Units: Participants]
Hispanic   1 
Black   2 
White   21 
[1] Race
Body Mass Index 
[Units: Kg/m^2]
Mean (Standard Deviation)
 27.2  (3.74) 
Ishak Fibrosis [1] 
[Units: Units on a scale]
Median (Full Range)
 (0 to 6) 
[1] Possible range is 0 to 6. Higher values represent worse outcomes.
[Units: Participants]
Cirrhosis   5 
Non-Cirrhosis   19 
Previous Therapy 
[Units: Participants]
Interferon/ribavirin   3 
Peginterferon/ribavirin   21 
Baseline HCV RNA Level 
[Units: Log10 (IU/mL)]
Mean (Standard Deviation)
 6.3  (0.6) 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Improvement in Viral Kinetics During the First 2 Weeks of Therapy   [ Time Frame: Days 7 to 14 of therapy ]

2.  Secondary:   2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).   [ Time Frame: 12 weeks from start of therapy ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information